JP2000506859A - 双極性障害の処置方法 - Google Patents

双極性障害の処置方法

Info

Publication number
JP2000506859A
JP2000506859A JP9532570A JP53257097A JP2000506859A JP 2000506859 A JP2000506859 A JP 2000506859A JP 9532570 A JP9532570 A JP 9532570A JP 53257097 A JP53257097 A JP 53257097A JP 2000506859 A JP2000506859 A JP 2000506859A
Authority
JP
Japan
Prior art keywords
bipolar disorder
olanzapine
effective amount
treating
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9532570A
Other languages
English (en)
Japanese (ja)
Inventor
ビーズリー，チャールズ・エム・ジュニア
トレフソン，ゲイリー・ディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2000506859A publication Critical patent/JP2000506859A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
JP9532570A 1996-03-11 1996-12-04 双極性障害の処置方法 Pending JP2000506859A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1315996P 1996-03-11 1996-03-11
US60/013,159 1996-03-11
PCT/US1996/019575 WO1997033577A1 (en) 1996-03-11 1996-12-04 Method for treating bipolar disorder

Publications (1)

Publication Number Publication Date
JP2000506859A true JP2000506859A (ja) 2000-06-06

Family

ID=21758606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9532570A Pending JP2000506859A (ja) 1996-03-11 1996-12-04 双極性障害の処置方法

Country Status (15)

Country Link
EP (1) EP0889725A4 (cs)
JP (1) JP2000506859A (cs)
KR (1) KR19990087713A (cs)
CN (1) CN1213966A (cs)
AU (1) AU734011B2 (cs)
BR (1) BR9612548A (cs)
CZ (1) CZ290298A3 (cs)
EA (1) EA000758B1 (cs)
HU (1) HUP9903679A3 (cs)
IL (1) IL126162A0 (cs)
NO (1) NO984189D0 (cs)
NZ (1) NZ326031A (cs)
PL (1) PL328925A1 (cs)
TR (1) TR199801797T2 (cs)
WO (1) WO1997033577A1 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101901A3 (en) * 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911068A (pt) * 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
CZ290298A3 (cs) 1999-10-13
PL328925A1 (en) 1999-03-01
TR199801797T2 (xx) 1998-12-21
EA000758B1 (ru) 2000-04-24
HUP9903679A2 (hu) 2000-04-28
NO984189L (no) 1998-09-11
EA199800819A1 (ru) 1999-02-25
AU734011B2 (en) 2001-05-31
AU1330797A (en) 1997-10-01
NO984189D0 (no) 1998-09-11
HUP9903679A3 (en) 2001-10-29
EP0889725A1 (en) 1999-01-13
IL126162A0 (en) 1999-05-09
WO1997033577A1 (en) 1997-09-18
NZ326031A (en) 2001-05-25
EP0889725A4 (en) 2000-01-19
KR19990087713A (ko) 1999-12-27
BR9612548A (pt) 1999-07-20
CN1213966A (zh) 1999-04-14

Similar Documents

Publication Publication Date Title
JP2000506859A (ja) 双極性障害の処置方法
JP2000506860A (ja) 自閉症の処置方法
US5744470A (en) Method for treating insomnia
EP0900085B1 (en) Treatment of excessive aggression with olanzapine
US6274636B1 (en) Method for treating a tic disorder
JP2000517287A (ja) 物質乱用の処置方法
JPH08325151A (ja) 食欲不振を治療する方法
JP2000506528A (ja) 不眠症の処置方法
US6071902A (en) Method for treating excessive aggression
CA2248905A1 (en) Method for treating bipolar disorder
GB2305859A (en) Treatment of obsessive-compulsive disorder
MXPA98007431A (en) Medications to treat the bipo disorder
GB2305860A (en) Anti-emetic
MXPA98007438A (en) Medications to treat the insom
HK1023053A (en) Method for treating excessive aggression